TY - JOUR
AU - Döhner, Hartmut
AU - Späth, Daniela
AU - Saadati, Maral
AU - Fiedler, Walter
AU - Götze, Katharina S
AU - Koller, Elisabeth
AU - Westermann, Jörg
AU - Vogel, Wichard
AU - Heuser, Michael
AU - Lübbert, Michael
AU - Tischler, Hans-Joachim
AU - Germing, Ulrich
AU - Teichmann, Lino Lars
AU - Fransecky, Lars
AU - Wölfler, Albert
AU - Nachbaur, David
AU - Hertenstein, Bernd
AU - Schroers, Roland
AU - Martens, Uwe M
AU - von Harsdorf, Stephanie
AU - Radsak, Markus P
AU - Aschauer, Gregor
AU - Weißhaar, Stefanie
AU - Corbacioglu, Andrea
AU - Schrade, Anika
AU - Gaidzik, Verena I
AU - Thol, Felicitas R
AU - Paschka, Peter
AU - Bullinger, Lars
AU - Benner, Axel
AU - Döhner, Konstanze
AU - Ganser, Arnold
TI - Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
JO - Blood
VL - nn
SN - 0006-4971
CY - Washington, DC
PB - American Society of Hematology
M1 - DKFZ-2026-00049
SP - nn
PY - 2026
N1 - epub
AB - Core-binding factor acute myeloid leukemia (CBF-AML) is associated with KIT mutations and deregulated expression of KIT.We report results from the randomized, open-label, phase 3 trial of intensive chemotherapy with or without the multi-kinase inhibitor dasatinib in adult patients with CBF-AML.Patients received '3+7' induction therapy, followed by 4 cycles of high-dose cytarabine; in the investigational arm, patients received dasatinib 100 mg QD on days 8-21 in induction, and on days 6-28 in consolidation cycles, followed by 12-month single-agent dasatinib 100 mg QD. Primary endpoint was event-free survival (EFS). Secondary endpoints included overall survival, relapse-free survival, and cumulative incidence of relapse.202 patients were randomly assigned to the standard arm (n=102) and to the dasatinib arm (n=100). Median age was 49 years (range, 18, 77); 94 patients had t(8;21), 108 had inv(16)/t(16;16); 58 (28.7
LB - PUB:(DE-HGF)16
C6 - pmid:41490515
DO - DOI:10.1182/blood.2025030722
UR - https://inrepo02.dkfz.de/record/307552
ER -